tradingkey.logo

Anteris Technologies Global Corp

AVR
查看詳細走勢圖
5.490USD
+0.270+5.17%
收盤 02/06, 16:00美東報價延遲15分鐘
197.98M總市值
虧損本益比TTM

Anteris Technologies Global Corp

5.490
+0.270+5.17%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+5.17%

5天

-8.04%

1月

+13.43%

6月

+51.66%

今年開始到現在

+10.02%

1年

-11.45%

查看詳細走勢圖

操作建議

Anteris Technologies Global Corp當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力穩定。當前估值合理,在醫療設備與耗材行業排名98/205位。機構持股佔比非常高,近一月多位分析師給出公司評級為買入。最高目標價為15.00。中期看,股價處於上升通道。近一個月,市場表現很強,技術面評分較高,但很強的走勢沒有得到基本面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Anteris Technologies Global Corp評分

相關信息

行業排名
98 / 205
全市場排名
261 / 4521
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Anteris Technologies Global Corp亮點

亮點風險
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
業績增長期
公司處於發展階段,最新年度總收入2.70M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入2.70M美元
估值合理
公司最新PE估值-2.35,處於3年歷史合理位
機構加倉
最新機構持股25.19M股,環比增加5.38%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉2.04K股

分析師目標

基於 4 分析師
買入
評級
15.000
目標均價
+173.22%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Anteris Technologies Global Corp新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Anteris Technologies Global Corp簡介

Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
公司代碼AVR
公司Anteris Technologies Global Corp
CEOPaterson (Wayne G)
網址https://anteristech.com/
KeyAI